Nanobots: Revolutionizing Cancer Annihilation at the Molecular Frontier

Cancer remains one of the world's deadliest diseases. According to the latest Global Cancer Statistics, an estimated 19.3 million new cases and nearly 10 million deaths occurred worldwide¹ in 2020.Demographic shifts, environmental pollution, and rising lifestyle-related risk factors are projected to drive rapid growth in global cancer incidence over the next two decades².Effective interventions are urgently needed to curb overall mortality. Conventional therapies like surgery, chemotherapy, and radiotherapy have improved survival for many patients. Yet they show limited efficacy against advanced metastatic cancers³.Immunotherapies mark a breakthrough in managing these cases, but low response rates temper their success⁴.Critically, both chemotherapy and immunotherapies are non-targeted, often killing tumour cells alongside healthy ones and causing severe, sometimes fatal, side effects⁵. The past three decades have witnessed a great expansion of research in the field of cancer nanomedicine⁶showed in Fig.1.

The central promise of nanorobotics is to move cancer therapy away from non-specific treatment and toward molecularly guided intervention. Instead of exposing the whole body to toxic doses, nanorobots can be engineered to bind to cancer-associated markers, deliver payloads only where needed, and support real-time imaging or monitoring.

Natural nanorobots existing in biological systems:

Over the past decades, nanotechnology has advanced dramatically, with novel nanotechnologies applied across diverse fields. Yet living organisms feature even more remarkable natural nanomachines—often called "bio nanorobots" ⁷.

These structures rotate and transport chemical loads along predetermined tracks with sonometer precision and high efficiency, enabling essential cellular functions. Many natural biological nanorobots harness energy, converting it into mechanical work within living systems⁸.

Fig.1: Historical timeline of major development in the field of cancer nanomedicine.

Most protein-based molecular nanorobots transform chemical energy from ATP (adenosine triphosphate) into mechanical motion⁹. ATP synthase, one of Earth's most abundant proteins, resides in chloroplast thylakoid membranes, mitochondrial cristae, and bacterial plasma membranes. As the final enzyme in oxidative phosphorylation, this nanomachine uses electrochemical gradients and proton flow to drive ATP synthesis from ADP and phosphate—powering its own rotation. Vital to human health, ATP synthase holds promise for treating cancer, bacterial infections, and obesity¹⁰.

P-glycoprotein (P-pg.), an ATP-binding cassette transporter, confers multidrug resistance to chemo drugs, particularly anticancer agents¹¹.As an efflux pump that has ATPase-like function to export chemo drugs out of cells, p-gp is overexpressed in tumour cells, and drugs can be delivered to the extracellular matrix with these pumpsP-gp, a 170-kD protein containing two amino acid chains, has a flexible structure capable of maintaining its rotational and translational motion in the efflux mechanism. Inhibition of this efflux activity has been one of the many aims in the exploitation of p-glycoprotein inhibitors. Many studies reported the p-gp inhibitors based on the information on the function and structure of p-glycoprotein¹¹.

Fig.2: Cancer tumours killed by nanorobots

Types of Nanorobots:

Nanorobotics can be classified in several ways depending on their design, function and application. Here are the main types explained clearly.

Sr. No.	Nanorobots types	Characteristics
01.	Pharmacyte12	A medical nanorobot with a diameter of 1–2 mm. Molecular indicators or chemotactic sensors are used to ensure the precision of the targeting system. They can be eliminated or recuperated through centrifuge nana pheresis after finishing the tasks.
02.	Microchips13	Nanorobots possess microchips which can conduct current signals once the molecules detect a disease. The benefits are the small charge to yield and simple to operate.
03.	Respirocyte14	A type of nanorobot that carries oxygen like an artificial red blood cell.The power is achieved through endogenous serum glucose
04.	Microbivores15	The nanorobot is flat and spheroidal in shape for nanomedical usesWith a diameter of 3.4 μm along its main axis and a diameter of 2.0 μm on the minor axis. It has the phagocytic capability which is almost 80-fold higher proficient than other macrophages
05.	Clottocytes16	They have the ‘instant’ hemostasis biological activity which is called artificial mechanical platelets.They also transport substances that assist in the coagulation process.
06.	Chromallocyte17	The renovation machine will first assess the condition by inspecting the cellular substances, actions, and works.These repair machines are capable of overhauling the complete cell.

Fig.3: Construction of Nanorobots

RECENT ADVANCES IN NANOROBOTICS FOR CANCER THERAPY:

Recent year (especially 2024 -2026) have seen rapid progress in nanorobotics, moving from basic drug delivery systems toward intelligent responsive and multifunctional nanomachines

1.DNAOrigami Based Smart Nanorobots²⁴

One of the most important breakthroughs is the development of DNA-BASED nanorobots.These nanorobots are built using DNA folding technique (DNA origami).They remain inactive in normal tissue and activate only in tumour environments.

Key Advancements:

• A “Hidden weapon nanorobots’’ activates only in acidic tumour conditions (low pH).
• It exposes cytotoxic peptides only near cancer cells, avoiding damage to healthy tissues.
• In animal studies, it reduce tumour growth by ~70%.

2. Stimuli- responsive nanorobots²⁵ (smart activation system):

 Modern nanobots respond to specific tumour microenvironment signals such as:

• pH(acidic tumours)
• Enzymes
• Temperature
• Light(photo-activation)

Key Innovations:

• Biodegradable particle coated with lipids and polymers
• Enhance circulation time and tumour targeting
• Real-time monitoring of treatment

3. AI-Integration and Autonomous Nanorobots²⁶

Artificial intelligence is now being integrated with nanorobotics.

Capabilities:

• Decision-making based on tumour signals
• Adaptive drug release
• Real-time navigation optimization

4. Biohybrid Nanorobots²⁷ (Living+Artifical Systems):

A cutting-edge innovation involves combining biological organisms with nanotechnology.

• Natural mobility inside the body
• Ability to cross biological barriers
• Enhanced tumour penetration

These systems mimics natural biological processes improving targeting efficiency.

Advantages of nanorobotics²⁸:

• Nanorobot-based drug delivery systems improve bioavailability of therapeutic agents.
• They enable targeted therapy, ensuring that only malignant (cancerous) cells are treated while sparing healthy tissues.
• Nanorobots can reach remote or inaccessible areas of the human body that are difficult to operate on using conventional surgical techniques.
• Since drugs are carried and released precisely at the required site, they provide a large interfacial area for efficient mass transfer, enhancing drug effectiveness.
• This approach is generally non-invasive or minimally invasive, reducing patient discomfort.
• Nanorobots can be computer-controlled, allowing precise adjustment of drug dose, frequency, and timing of release.
• They offer high accuracy and precision in treatment.
• Drugs remain inactive in non-target areas, thereby minimizing unwanted side effects.
• Due to their extremely small size (up to ~3 microns), nanorobots can move easily through blood vessels without blocking capillary flow.
• They can become cost-effective when produced on a large scale, as batch manufacturing reduces overall costs despite high initial development expenses.

Applications of nanorobots in cancer treatment^29,30:

Early diagnosis significantly increases a patient’s chances of successful cancer treatment. Nanorobots equipped with chemical biosensors (nanosensors) can be used to detect tumour cells at an early stage of cancer development. These nanosensors are capable of identifying the presence of malignant cells within the body with high sensitivity.Most anticancer drugs have a narrow therapeutic index, which often leads to toxicity in normal cells, especially stem cells. This can result in adverse effects such as hematological toxicity and gastrointestinal complications. Conventional chemotherapeutic agents act by destroying rapidly dividing cells, a characteristic feature of cancer (neoplastic) cells. However, this mechanism also affects healthy rapidly dividing cells. Drugs such as Doxorubicin are widely used in the treatment of various cancers, including Hodgkin’s disease. These drugs are often administered in combination with other anticancer agents to enhance therapeutic efficacy and reduce toxicity.

Nanorobots, due to their ability to function as blood-borne devices, can play a crucial role in improving cancer therapy. Nanorobots integrated with chemical biosensors can detect tumor cells in the early stages within the patient’s body. Advanced nanosensors can also measure the intensity of specific biomarkers, such as E-cadherin signals, which are important in cancer detection and progression. This has led to the development of hardware architectures based on nano-bioelectronics for the application of nanorobots in cancer diagnosis and therapy.

In addition, scientists have developed biohybrid systems using genetically modified Salmonella bacteria that are naturally attracted to tumor environments due to chemicals secreted by cancer cells. These bacteria carry microscopic robots, approximately 3 micrometers in size, which can automatically release drug-filled capsules upon reaching the tumor site. This system, often referred to as a bacteriobot, enables targeted drug delivery directly to the tumor, thereby destroying cancer cells while minimizing damage to healthy tissues and reducing the side effects associated with conventional chemotherapy.

CONCLUSION

Nanorobotics has emerged as a revolutionary approach in precision cancer therapy by offering targeted, efficient and minimally invasive treatment strategies. This review article highlighted the fundamental concepts of nanorobotics including its introduction, historical perspective, various types, construction, advanced technologies, and wide-ranging applications in cancer diagnosis and treatment. The integration of nanotechnology, artificial intelligence, biosensors, and drug delivery systems has significantly improved the ability of nanorobots to detect cancer cells at an early stage and deliver therapeutic agents directly to tumour tissues greater accuracy and reduced side effects.

Furthermore, advanced developments in molecular engineering and biomedical sciences have expanded the potential of nanorobotics in personalised medicine, controlled drug release, imaging and real-time monitoring of caner progression. Although several challenges such as biocompatibility, safety, manufacturing complexity, ethical concerns, and high cost still remain, continuous research and technological advancements are expected to overcome these limitations in the future.

Overall, nanorobotics represents a promising and futuristic platform for precision oncology, with the potential to transform conventional cancer therapy into a more effective, safer, and patient-specific treatment approach. Continued interdisciplinary research and clinical investigations will play a vital role in bringing nanorobotic cancer therapy from experimental stages to routine clinical practice.

ACKNOWLEDGEMENT:

We would like to express my sincere gratitude to our Principal Dr. M. Venkataramana, for providing all the necessary facilities and continuous encouragement for the successful completion of our work.

We are deeply thankful to Vice Principal and our guide “Dr. A.Ganesh" for his valuable guidance, continuous encouragement, and constant support throughout the preparation of this article.

We also extend our heartfelt thanks to all the faculty members and our friends for their cooperation, motivation, and assistance during the completion of this work.

Finally, we thank everyone who directly or indirectly contributed to the successful completion of our article.

REFERENCES

1. Divya Sahejwani, Achal S. Satpute, Amol V. Sawale. Research Journal of Science and Technology.
2. Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA CancerJ. Clin. 71, 209–249 (2021).
3. Gotwals, P. et al. Prospects for combining targeted and conventional cancer therapy with immunotherapy. Nat. Rev. Cancer 17, 286–301 (2017).
4. Nam, J. et al. Cancer nano medicine for combination cancer immunotherapy. Nat. Rev. Mater. 4, 398–414 (2019).
5. Riley, R. S., June, C. H., Langer, R. & Mitchell, M. J. Delivery technologies for cancer immunotherapy. Nat. Rev. Drug Discov. 18, 175–196 (2019).
6. Bangham, A. D. & Horne, R. W. Negative staining of phospholipids and their structural modification by surface-active agents as observed in the electron microscope. J. Mol. Biol. 8, 660-IN610 (2024).
7. Sanchez S, Pumera M. Nanorobots: the ultimate wireless self-propelled sensing and actuating devices. Chem Asian J. 2009;4:1402–1410. doi:10.1002/asia.200900143.
8. Hullmann A. Who is winning the global nanorace? Nat Nanotechnol. 2006;1:81–83. doi: 10.1038/nnano.2006.110.
9. Van den Heuvel MG, Dekker C. Motor proteins at work for nanotechnology. Science. 2007;317:333–336. doi: 10.1126/science.1139570.
10. Ahmad Z, Laughlin TF. Medicinal chemistry of Atp synthase: a potential drug target of dietary polyphenols and amphibian antimicrobial peptides. Curr Med Chem. 2010;17:2822–2836. doi: 10.2174/092986710791859270.
11. Gillet JP, Gottesman MM. Mechanisms of multidrug resistance in cancer. Methods Mol Biol. 2010;596:47–76. doi: 10.1007/978-1-60761-416-6_4.
12. Mani SA, Sachdeva S, Mani A, Vora HR, Sodhi JK. Nano-robotics: the future of health and dental care. IP Int J PeriodontolImplantol. 2021;6:6–10. doi: 10.18231/j.ijpi.2021.002.
13. Žnidaršič AB, Alenka B, Werber B. Attitudes toward microchip implant in groups pro and con its insertion for healthcare purposes. BLED 2020 Proc 1. 2020.
14. Kumar JPS, Sankaranarayanan R, Sujana JAJ, Hynes NRJ. advantages and disadvantages of nanodevices. In: Verpoort F, Ahmad I, Ahmad A, Khan A, Chee CY, editors. Nanomedicine manufacturing and applications. Elsevier. 2021; p. 163–71.
15. Gandhi M, Joshi PN. Nanorobots for in vivo monitoring: the future of nano-implantable devices. In: Chandra P, Prakash R, editors. Nano biomaterial engineering. Singapore: Springer Singapore; 2020. pp. 227–252.
16. Javaid A. Medical nanorobots: our new healthcare defense. Acad Lett. 2021;2021:1629.
17. Sapra V, Sapra L, Sandhu JK, Chhabra G. Biomedical diagnostics through nano computing. In: Nanotechnology. Jenny Stanford Publishing; 2021. p. 443–460
18. Feynman RP. There's plenty of room at the bottom. Eng Sci. 1960;23(5):22-36.
19. Freitas RA Jr. Nanomedicine, Volume 1: Basic Capabilities. Landes Bioscience; 1999.
20. Douglas SM, et al. Rapid prototyping of 3D DNA-origami shapes with caDNAno. Nature. 2009;459(7245):414-418.
21. Han D, et al. DNA origami with complex curvatures in three dimensions. Science. 2011;332(6027):342-346.
22. Rothemund PW. Folding DNA to create nanoscale shapes and patterns. Nature. 2006;440(7082):297-302.
23. List J, et al. Tailored DNA nanostructures for cancer therapy. ACS Nano. 2014;8(7):6710-6718.
24. Wang Y, Baars I, Berzina I, et al. A DNA robotic switch with regulated autonomous display of cytotoxic ligand nanopatterns. Nature Nanotechnology. 2024. DOI: 10.1038/s41565-024-01676-4.
25. Negut I, Bita B. Polymersomes as Innovative, Stimuli-Responsive Platforms for Cancer Therapy. Pharmaceutics. 2024;16(4):463. DOI: 10.3390/pharmaceutics16040463.
26. Sharma PK, Chen CY. AI-Integrated Micro/Nanorobots for Biomedical Applications: Recent Advances in Design, Fabrication, and Functions. Biosensors. 2025;15(12):793. DOI: 10.3390/bios15120793.
27. Park S, Barak N, Lotan T, Yossifon G. Bio hybrid Microrobots Based on Jellyfish Stinging Capsules and Janus Particles for In Vitro Deep-Tissue Drug Penetration. 2024.
28. Jhansee Mishra1, Alok Kumar Dash and Rajeev Kumar, “Nanotechnology Challenges; Nano medicine: Nanorabots”. Int. Res. J. of Pharmaceuticals, 2012; 02(04): 112-119 ISSN2048-4143:112-119.
29. Meena Kharwade, Monika Nijhawan, and Sheela Modani. “Nanorobots: A Future Medical Devicein Diagnosis and Treatment”. Research Journal of Pharmaceutical, Biological andChemical Sciences: ISSN: 0975-8585 April - June 2013; RJPBCS Volume 4 Issue 2:1229-1307.
30. Rohit Kumar, Omprakash Baghel, Sanat Kumar, Sidar Prakash Kumar Sen, Shailendra Kumar Bohidar. “Applications of Nanorobotics”. International Journal of Scientific Research Engineering & Technology (IJSRET), ISSN 2278 – 0882: November 2014; 3(8): 1131-1136.